Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics

Annals of Pharmacotherapy

Volumn 39, Issue 11, 2005, Pages 1844-1851

  Devlin, John W ^a,b   Welage, Lynda S ^c   Olsen, Keith M ^d  

^a NORTHEASTERN UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Lansoprazole; Omeprazole; Pantoprazole; Proton pump inhibitors: esomeprazole; Rabeprazole; Stress ulcer prophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; BICARBONATE; CEFPODOXIME PROXETIL; CIMETIDINE; DIAZEPAM; DIDANOSINE; DIGOXIN; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE; WARFARIN;

ABDOMINAL PAIN; ACID SECRETION; ACUTE DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIARRHEA; DRUG EFFICACY; DRUG FORMULARY; DRUG FORMULATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HOSPITAL INFECTION; HUMAN; HYPOPHOSPHATEMIA; INFECTION; INTENSIVE CARE; METABOLIC ALKALOSIS; NAUSEA; PEPTIC ULCER; PNEUMONIA; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STRESS ULCER; TREATMENT INDICATION; TREATMENT OUTCOME; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACUTE DISEASE; ANTI-ULCER AGENTS; CAPSULES; HUMANS; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; TABLETS;

EID: 27344452930     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G176     Document Type: Review

References (78)

1. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole and rabeprazole in the treatment of acid-related disorders. J Am Pharm Assoc 2000;40:52-62.
2. Metz DC, Pratha V, Martin P, Paul J, Maton PN, Lew E, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000;95:626-33.
3. Pisegna JR. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Crit Care Med 2002;30(suppl):S356-61.
4. Conrad SA. Acute upper gastrointestinal bleeding in critically ill patients: causes and treatment modalities. Crit Care Med 2002;30(suppl): S365-8.
5. Hellstrom PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol 2004;94:106-11.
6. Pisegna JR. Switching between intravenous and oral pantoprazole. J Clin Gastroenterol 2001;32:27-32.
7. Zuckerman MB. A prescription for sanity. US News World Rep 2004; (Nov 22)137:80.
8. Kaplan GG, Bates D, McDonald D. Inappropriate use of intravenous proton pump inhibitors: problem extent and cost implications (abstract). Am J Gastroenterol 2002;97(suppl):S236.
9. Enns R, Andrews CN, Fishman M, Hahn M, Atkinson K, Kwan P, et al. Description of prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicenter study. Can J Gastroenterol 2004;18:561-71.
10. Cornish P, Papastergiou J, Saibil F. Audit of IV pantoprazole: patterns of use and compliance with guidelines. Can J Hosp Pharm 2002;55:20-6.
11. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 2005_
12. Package insert. Nexium (esomeprazole). Wilmington, DE: AstraZeneca PLC. www.astrazeneca-us.com/pi/Nexium.pdf (accessed 2005 May 12).
13. Package insert. Prevacid (lansoprazole). Lake Forest, IL: TAP Pharmaceutical Products. www.pitap.abbott.com/prevacid.pdf (accessed 2005 May 12).
14. Package insert. Prilosec (omeprazole). Wilmington, DE: AstraZeneca PLC. www.astrazeneca-us.com/pi/Prilosec.pdf (accessed 2005 May 12).
15. Package insert. Aciphex (rabeprazole). Titusville, NJ: Janssen Pharmaceutica. www.janssen.com/active/janus/en_US/assets/jan/aciphex.pdf (accessed 2005 May 12).
16. Package insert. Protonix (pantoprazole) delayed release tablet. Madison, WI: Wyeth Pharmaceuticals. www.wyeth.com/content/ShowLabeling. asp?id=135 (accessed 2005 May 12).
17. DeVault KR, Castell DO, for the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200.
18. Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004;117 (suppl):63S-71S.
19. Package insert. Zegerid (omeprazole). San Diego: Santaras. www.santaras. com/pdf/package_insert.pdf (accessed 2005 May 12).
20. Package insert. Protonix IV (pantoprazole). Madison, WI: Wyeth Pharmaceuticals. www.wyeth.com/content/ShowLabeling.asp?id=469 (accessed 2005 May 12).
21. Package insert. Prevacid IV (lansoprazole). Lake Forest, IL: TAP Pharmaceutical Products, www.pitap.abbott.com/prevacidiv.pdf (accessed 2005 May 12).
22. Kovacs TO, Lee CQ, Chiu YL, Pilmer BL, Metz DC. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. Aliment Pharmacol Ther 2004;20:883-9.
23. Package insert. Nexium IV (esomeprazole). Wilmington, DE: AstraZeneca PLC. www.astrazeneca-us.com/pi/Nexium.pdf (accessed 2005 May 12).
24. Schneider H, Van Rensburg C, Schmidt S, Aboo N, Makela H, Naucler E, et al. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis. Digestion 2004;70:250-6.
25. Hung PD, Schubert ML, Mihas AA. Zöllinger-Ellison syndrome. Curr Treat Options Gastroenterol 2003;6:163-70.
26. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin M, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zöllinger-Ellison syndrome. Gastroenterology 2000;118:696-704.
27. Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zöllinger-Ellison syndrome. Am J Gastroenterol 2001;96:3274-80.
28. Schumann RB, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med 1987;106:562-7.
29. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994;330:377-81.
30. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. Am J Health Syst Pharm 1999;56:347-79.
31. Daley RJ, Rebuck JA, Welage LS, Rogers F. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004;32:2008-13.
32. Lam NP, Le PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Crit Care Med 1999;27:98-103.
33. Martin LF, Booth FV, Karlstadt RG, Silverstein JH, Jacobs DM, Hampsey J, et al. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993;21:19-30.
34. Phillips JO, Metzler MH, Palmieri MT, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-800.
35. Lasky MJ, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998;44:527-33.
36. Roberts KW, Pitcher WD, Cryer B. Effect of lansoprazole suspension versus continuous intravenous ranitidine on gastric pH of mechanically ventilated intensive care unit patients (abstract). Crit Care Med 2000;28:567.
37. Phillips JO, Metzler MH, Huckfeldt RE, Olsen KM. A multicenter, prospective, randomized clinical trial of continuous infusion I.V. ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcers (abstract). Crit Care Med 1998;26(suppl):A101.
38. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997;42:1255-9.
39. Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother 2002;36:1929-37. DOI 10.1345/aph.1C151
40. Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO, et al. Randomized, double-blind comparison of immediate-release omeprazole-oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005;33:760-5.
41. Welage LS, Ellis J, Alaniz C. Gastrointestinal alterations in the critically ill. Pharm Pract News 2003;7(8):46-51.
42. Somberg L, Karlstadt R, Blatcher D. Intermittent intravenous pantoprazole maintains control of gastric pH in intensive care unit patients (abstract). Am J Gastroenterol 2002;97(suppl):S47.
43. Barkun AN, Bardou M, Marshall JK. Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-57.
44. Green FW, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978;74:38-43.
45. 2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002;16:1137-42.
46. Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004;(3):CD002094.
47. Lau JY, Leung WK, Wu JC, Chan FK, Wong V, Hung LC, et al. Early administration of high-dose intravenous omeprazole prior to endoscopy in patients with upper gastrointestinal bleeding: a double-blind, placebo-controlled, randomized trial (abstract 347). Presented at: 2005 Digestive Disease Week Meeting, Chicago, IL, May 15-18, 2005.
48. Erstad BL. Proton-pump inhibitors for acute peptic ulcer bleeding. Ann Pharmacother 2001;35:730-40. DOI 10.1345/aph.10306
49. Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 1992;304:143-7.
50. Villanueva C, Balanzo J, Torras X, Sainz S, Soriano G, Gonzalez D, et al. Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study. Endoscopy 1995;27:308-12.
51. Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000;343:310-6.
52. Barkun A, Racz I, van Rensburg C, Beglinger C, Kupcinskas L, Schaefer-Preuss S, et al. Prevention of peptic ulcer rebleeding using continuous infusion of pantoprazole vs ranitidine: a multicenter, multinational, randomized, double-blind, parallel-group comparison (abstract). Gastroenterology 2004;126:A78.
53. Hsu PI, Lo GH, Lo CC, Lin CK, Chan HH, Wu CJ, et al. Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers. World J Gastroenterol 2004;10:3666-9.
54. Chan EP, Goebig M, Demers RF, Katzka DA, Metz DC. Intravenous pantoprazole to prevent rebleeding after endoscopic hemostasis of bleeding ulcers: initial U.S. experience (abstract). Gastroenterology 2003;124(4 suppl 1):A626.
55. Khuroo MS, Yattoo GN, Javid G, Khan BA, Shah AA, Gulzar GM, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997;336:1054-8.
56. Javid G, Masoodi I, Zargar SA, Khan BA, Yatoo GN, Shah AH, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001;111:280-4.
57. Kaviani MJ, Hashemi MR, Kazemifar AR, Roozitalab S, Mostaghni AA, Merat S, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003;17:211-6.
58. Nguyen CM, Barletta JF, Devlin JW. Use of acid suppression agents following acute, non-variceal, upper gastrointestinal bleeding. Hosp Pharm 2004;39:970-5.
59. McAndrews KL Jr, Eastham JH. Omeprazole and lansoprazole suspensions for nasogastric administration. Am J Health Syst Pharm 1999;56:81.
60. Sandvik AK, Brenna E, Waldum HL. The pharmacologic inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther 1997;11:1013-8.
61. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-8.
62. Navab F, Steingrub J. Stress ulcer: is routine prophylaxis necessary? Am J Gastroenterol 1995;90:708-12.
63. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998;338:791-7.
64. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60.
65. Stedman CA, Barclay ML. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78.
66. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40:523-37.
67. Welage LS. Pharmacologic properties of the proton pump inhibitors: comparing the agents. Pharmacotherapy 2003;23(suppl):74S-80S.
68. Welage LS, Berardi RR. Drug interactions with antiulcer agents: considerations in the treatment of acid-peptic disease. J Pharm Pract 1994;6:177-95.
69. Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990;29:557-63.
70. Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000;56:665-70.
71. Schupp KN, Schrand LM, Mutnick AH. A cost-effectiveness analysis of stress ulcer prophylaxis. Ann Pharmacother 2003;37:631-5. DOI 10.1345/aph.1C377
72. Lee KK, You JH, Wong IC, Kwong SK, Lau JY, Chan TY, et al. Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. Gastrointest Endosc 2003;57:160-4.
73. Spiegel BM, Ofman JJ, Woods K, Vakil NB. Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies. Am J Gastroenterol 2003;98:86-97.
74. Barkun AN, Herba K, Adam V, Kennedy W, Fallone CA, Bardou M, et al. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004;19:591-600.
75. Enns RA, Gagnon YM, Rioux KP, Levy AR. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2003;17:225-33.
76. Gagnon YM, Levy AR, Eloubeidi MA. Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding. Value Health 2003;6:457-65.
77. Erstad BL. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med 2004;32:1277-83.
78. Devlin JW, Welage LS. The cost-effectiveness of proton pump inhibitors for bleeding peptic ulcers: the unanswered questions. Crit Care Med 2004;32:1415.